BIVI Insider Trading
Insider Ownership Percentage: 4.00%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00
BioVie Share Price & Price History
Current Price: $0.98
Price Change: ▲ Price Increase of +0.144 (17.14%)
As of 04/2/2025 03:35 PM ET
BioVie Insider Trading History
BioVie Institutional Trading History
Data available starting January 2016
BioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.
Read More on BioVie
Volume
218,116 shs
Average Volume
1,742,643 shs
Market Capitalization
$18.16 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.51
Who are the company insiders with the largest holdings of BioVie?